Immunic, Inc. · NASDAQ:IMUX
Immunic — 16th World Immune Regulation Meeting 2022
14 slides from Immunic's conference presentation, Jul 9, 2022
Slide 1: IMU-935, an Orally Available RORgt Inverse Agonist in Phase 1 Clinical Trial for Psoriasis
IMU-935, an Orally Available RORgt Inverse Agonist in Phase 1 Clinical Trial for Psoriasis, Inhibits Th17-Dependent Autoimmunity without Inducing Thymocyte Aberrations Evelyn Peelen, Ph.D. | Immunic Therapeutics | NASDAQ: IMUX July 09, 2022 | 16th World Immune Regulation Meeting 2022
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Slide 3: IMU-935 Overview: Introduction
1 IMU-935 Overview Mode of Introduction Action – In vitro Mode of Conclusions Action – In vivo
Slide 4: The Nuclear Receptor RORgamma
The Nuclear Receptor RORgamma v Retinoic acid receptor-related orphan receptor (ROR) gamma (RORg) is encoded by the RORC gene v It consists of two isoforms v RORg1: full length 518 aa v RORgt (RORg2): lacks the first 21 aa. It is mainly expressed by T cells, but also in some other immune cells and i
Slide 5: IMU-935 Overview: Mode of Action – In vitro
2 IMU-935 Overview Mode of Introduction Action – In vitro Mode of Conclusions Action – In vivo
Slide 6: Potently Inhibits TH17 Cell Differentiation but Does Not Induce Thymocyte Apoptosis
IMU-935 Potently Inhibits TH17 Cell Differentiation but Does Not Induce Thymocyte Apoptosis In Contrast to IMU-935, Comparator Compounds Have a Negative Impact on Thymocyte IL-17F Viability and Therefore Bear the Risk of Lymphoma. RORgt-/- DMSO IM105935 * *** ** MRL-871 Cintirorgon (agonist) 140 Cpd
Slide 7: Blocks Th17 Differentiation But Allows Normal Thymocyte Maturation: Gene Expression Profiles
IMU-935 Blocks Th17 Differentiation But Allows Normal Thymocyte Maturation: Gene Expression Profiles Thymocytes Th17 cell WT + RORγt-/- WT IMU-935 RORγt+/+- RORγt-/- RORγt+/+ IMU-935 IMU-935 Apoptosis Th17 signature genes Anti-apoptosis/ survival Similar gene expression pattern for Th17 signature Di
Slide 8: Potently Inhibited Cytokine Release in Ex Vivo Stimulated Human Skin Punches
IMU-935 Potently Inhibited Cytokine Release in Ex Vivo Stimulated Human Skin Punches Cytokine Inhibition in Inflamed Human Skin Model IMU-935 is active with < 100 nM on GM-CSF IL-17A IL-17F Method: Result: Skin punches from a human healthy volunteer were ex vivo IMU-935 demonstrated a strong inhibit
Slide 9: IMU-935 Overview: Mode of Action – In vivo
3 IMU-935 Overview Mode of Introduction Action – In vitro Mode of Conclusions Action – In vivo
Slide 10: Demonstrated Activity in an Imiquimod Induced Psoriasis Model
IMU-935 Demonstrated Activity in an Imiquimod Induced Psoriasis Model 5 mg/kg 5 mg/kg 5 mg/kg 5 mg/kg Female 10/100 mg/kg § IMU-935 benchmarked with an IL-17A antibody (InVivoMab, Clone: 17F3) 50 mg 5% IMQ demonstrating superiority of IMU-935 on skin thickness at day 8 BALB/cJ § Interestingly, the a
Slide 11: Allows Normal Thymocyte Maturation In Vivo
IMU-935 Allows Normal Thymocyte Maturation In Vivo § Acute model: Treatment with IMU-935 (100 mg/kg), MRL-871 (100 mg/kg) and Cintirorgon (30 15 mg/kg) for 3 days (BID) Thymic cellularity (x107) 12 9 In contrast to 6 ** MRL-871 and Cpd1, IMU-935 does not impact 3 0 thymus size, thymocyte cell Vehicl
Slide 12: IMU-935 Overview: Conclusions
4 IMU-935 Overview Mode of Introduction Action – In vitro Mode of Conclusions Action – In vivo
Slide 13: Selectively Inhibits Th17 Differentiation and IL-17 Secretion
IMU-935 Selectively Inhibits Th17 Differentiation and IL-17 Secretion The differentiation towards Th17 cells is inhibited by IMU-935 The production of IL-17A and IL-17F is inhibited by IMU-935 The physiological maturation of T cells within the thymus is not affected by IMU-935 Th: T helper; IL: inte
Slide 14: Thank You!
Thank You! Immunic, Inc. 1200 Avenue of the Americas Immunic AG New York City, NY 10036 Gräfelfing (Munich) USA Germany Immunic Research GmbH Weinberg Campus Evelyn Peelen, Ph.D. Halle (Saale) Germany Senior Manager Translational Collaborators Pharmacology at City of Hope Phone: +49 89 2080 477 27 P